Cardiovascular risk factors in patients with type 2 diabetes mellitus in Kenya: Levels of control attained at the outpatient diabetic Clinic of Kenyatta National Hospital, Nairobi

East African Medical Journal

Volumn 82, Issue 12 SUPPL., 2005, Pages

  Otieno, C F ^a   Vaghela, V ^b   Mwendwa, F W ^c   Kayima, J K ^a   Ogola, E N ^a  

^a UNIVERSITY OF NAIROBI   (Kenya)

^b Department of Obstetrics and Gynaecology   (Kenya)

^c Upper Hill Medical Centre ^*

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CROSS-SECTIONAL STUDY; DIABETIC ANGIOPATHY; FEMALE; HUMAN; KENYA; MALE; MEDICINE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTPATIENT DEPARTMENT; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR;

CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; HUMANS; KENYA; MALE; MIDDLE AGED; OUTPATIENT CLINICS, HOSPITAL; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SPECIALTIES, MEDICAL;

EID: 33644583739     PISSN: 0012835X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Zimmet, P. and Alberti, K. G. M. M. The changing face of macrovascular disease in NIDDM. Lancet. 1997; 350 (suppl. 1): 1-4.
2. Eastman, R. C. and Keen, H. The impact of cardiovascular disease on people with diabetes: the potential for prevention. Lancet 1997; 350 (Suppl. 1): 29-32.
3. UKPDS group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998; 352: 832-853.
4. Sacks, F. M., Pfeffer, M. A., Moye, L. A., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial. N. Eng. J. Med. 1996; 335: 1001-1009.
5. Heart Outcomes Prevention Evaluation study investigators: Effects of an angiotensin converting enzyme-inhibitor, ramipril, on death from cardiovascular events in high-risk patients. N. Eng. J. Med. 2000; 342: 145-153.
6. Gaede, P., Vedel, P., Larsen, N. et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N. Eng. J. Med. 2003; 348: 383-393.
7. World Health Organization. Definition, diagnosis and classification of Diabetes mellitus and its complications. Report of a WHO consultation. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Geneva, Switzerland: World Health Organization.; 1999.
8. Chobanian, A. V., Bakris G. L., Black H. R., et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of high blood pressure. The JNC VII Report. JAMA. 2003; 289: 2560-2572.
9. Friedewald, T., Levy, R. I. and Fredrickson, D. S. Estimation of the concentration of LDL-C in plasma without use of preparative ultracentrifuge. Clin. Chem. 1972; 18: 499-502
10. American Diabetes Association. Economic consequences of diabetes mellitus in the US in 2002. Diabetes Care. 2003; 26: 917-932
11. Klein, R. and Klein, B. E. K. Vision disorders in diabetes. In: National Diabetes Data Group, ed. Diabetes in America. 2nd ed. Bethesda, Md: National Institute of Diabetes and Digestive and Kidney Diseases; 1995: 293-338.
12. Klein, R. Hyperglycaemia and microvascular and macrovascular disease in diabetes. Diabetes Care. 1995; 18: 258-268.
13. ADA. Management of dyslipidaemia in adults with diabetes. Diabetes Care 2002; 25: 574-577.
14. Wingard, D. and Barrett-Connor, E. Heart disease and diabetes. In: National Diabetes Data Group, ed. Diabetes in America. 2nd ed. Bethesda, Md: National Institute of Diabetes and Digestive and Kidney Diseases; 1995: 429-448.
15. Stratton, I. M., Adler, A. I., Neil, H. A., et al. Association of glycaemia and macrovascular and microvascular complications in type 2 diabetes (UKPDS 35): prospective observational study. Brit. Med. J. 2000; 321: 405-412.
16. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 1993; 329: 977-986.
17. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998; 352: 837-853.
18. Wei, M., Gaskill, S. P., Haffner, S. M., et al. Effects of diabetes and level of glycaemia on all-cause and cardiovascular mortality: the San Antonio Heart Study. Diabetes Care. 1998; 21: 1167-1172.
19. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Effect of intensive therapy on the microvascular complications of type I diabetes mellitus. JAMA. 2002; 287: 2563-2569.
20. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N. Engl. J. Med. 2003; 348: 2294-2303.
21. UK Prospective Diabetes Study (UKPDS) Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Brit. Med. J. 1998; 317: 703-713.
22. Hansson, I., Zanchetti, A., Carruthers, S. G., et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet. 1998; 351: 1755-1762.
23. Pyorala, K., Pedersen, T. R., Kjekshus, J., et al. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care. 1997; 20: 614-620.
24. Huang, E. S., Meigs, J. B. and Singer, D. E. The effect of interventions to prevent cardiovascular disease in patients with type 2 diabetes mellitus. Amer. J. Med. 2001; 11: 632-642.
25. Nachtigal, J. D. and Carroll, C. A. Economic Implications of Diabetes mellitus. In: Diabetes and Cardiovascular Disease. Eds. Steven P Marso & David M. Stern. Lippincott Williams & Wilkins, Philadelphia. 2004. Chapter 10, pp179-197.
26. Saydah, S. H., Fradkin, J. and Cowie, C. C. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004; 291: 335-342.
27. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care 2002; 25(Suppl.1):S33-S49.
28. Pringle, M., Stewart-Evans, C., Coupland, C., Allison, S. and Sterland, J. Influence on control in diabetes mellitus: patient, doctor, practice or delivery of care? Brit. Med. J. (1993); 306: 630-634
29. Probert, C. S. I., Maddison, W. and Roland, J. M. Diet, diabetes and male chauvinism. Brit. Med. J. 1990; 301: 1430-1431.
30. Graves, J. W. Management of difficult to control hypertension. Mayo. Clin. Proc. 2000; 75: 278-284.
31. Winickoff, R. N. and Murphy, P. K. The persistent problem of poor blood pressure control. Arch. Intern. Med. 1987; 147: 1393-1396.
32. Miller, N. H. Compliance with treatment regimens in chronic asymptomatic diseases. Amer. J. Med. 1997; 102: 43-49.
33. Tuomilehto, J., Rastenyte, D., Birkenchager, W. H., et al. Systolic hypertension in Europe Trial investigators. Effects of calcium channel blockers in old patients with diabetes and systolic hypertension. N. Engl. J. Med. 1999; 340: 677-684.
34. Lin, E. H. B., Katon, W., von Korff, M., et al. Relationship of depression and diabetes self-care, medication adherence and preventive care. Diabetes Care 2004; 27: 2154-2160.
35. Grant, R. W., Cagliero, E., Dubey, A. K., et al. Clinical inertia in the management of type 2 diabetes metabolic risks. Diabet Med. 2004; 21: 150-155.
36. The Long-term Intervention with Pravastain in Ischaemic Disease (LIPID) study group. Prevention of cardiovascular events and death with pravastian in patients with coronary heart disease and a broad range of initial cholesterol levels. N. Eng. J. Med. 1998; 339: 1349-1357.
37. Baseline risk factors and their association with outcome in the West of Scotland Coronary Prevention Study. The West of Scotland Coronary Prevention Study Group. (WOSCOPS). Amer. J. Cardiol. 1997; 79: 756-762.
38. Fornengo, P., Bruno, G., De Salvia, A., et al. Low adherence of General practitioners to NCEP guidelines for the management of hyperlipidaemia. Diab. Nutr and Metab. 2000; 13: 263-268.
39. Stafford, R. S., Blumenthal, D. and Pastenak, R. C. Variations in cholesterol management practices in United States physicians. J. Amer. Coll. Cardiol. 1997; 29: 139-146.
40. Shepherd, J. and Pratt, M. Prevention of coronary heart disease in clinical practice: a commentary on current treatment patterns in six European countries in relation to published recommendations. Cardiology 1996; 87: 1-5.
41. Turner, R. C., Cull, C. A., Frighi, V. and Holman, R. R., for UKPDS group. Glycaemic control with diet, sulphonylurea, met forming, or insulin in patients with type 2 diabetes mellitus. Progressive requirement for multiple therapies (UKPDS 49). JAMA 1999; 281: 2005-2012.
42. Chan, J. L. and Abrahamson, M. J. Pharmacological management of type 2 diabetes mellitus. Rational for rational use of insulin. Mayo. Clin. Proc. 2003; 78: 459-467.
43. Torpy, J. M. Integrating complimentary therapy into care. JAMA 2002; 287: 306-307.
44. American Diabetes Association: Clinical practice recommendations. Diabetes care 2003; 23 (suppl): S1-S133.
45. Grant, R. W., Cagliero, E., Murphy-Sheeny, P., et al. Comparison of hyperglycaemia, hypertension and hypercholesterolemia management in patients with type 2 diabetes. Amer. J. Med. 2002; 112: 603-609.
46. Burt, V. L., Whelton, P., Roccella, E. J., et al. Prevalence of hypertension in the US adult population. Hypertension 1995; 25: 305-313.
47. Rahman, M., Douglas, J. G. and Wright, J. T. Pathophysiology and treatment implications of hypertension in the African-American population. Endocrinol Metab. Clin. North. Amer. 1997; 26: 125-144.
48. Klag, M. J., Whetton, P. K., Randall, B. L., et al. Endstage renal disease in African-American and white men: 16 year multiple risk factor intervention study findings. JAMA 1997; 277: 1293-1298.
49. The ALLHAT officers and coordinators for ALLHAT collaborative group. Major outcomes in high-risk hypertensive patients randomized to angiotensin converting enzyme-inhibitor calcium channel blocker versus diuretic. The Antihypertensive and Lipid-Lowering to prevent Heart Attack Trial. JAMA 2002; 288: 2981-2997.
50. Cushman, W. C., Ford, C. E., Culter, J. A., et al. Success and predictors of blood control in diverse North American settings. ALLHAT. J. Clin. Hypertens (Greenwich). 2002; 4: 393-405.
51. Williams, B. The renin-angiotensin system and cardiovascular disease: Hope or Hype? JRAAS. 2001; 1: 42-46.
52. Carrol, C., Naylor, E., Marsden, P. and Dornan, T. How do people with type 2 diabetes perceive and respond to cardiovascular risk? Diabet. Med. 2003; 20: 355-360.
53. Rubin, R. R., Anderson, R. M. and Funnel, M. M. Collaborative diabetes care. Practical diabetes 2002; 21: 29-37.